UK orders thermal imagers
Theon Sensors has obtained a contract from the UK MoD to supply an initial 500 units of its Thermis CS clip-on thermal imaging sight.
Thermis CS will meet the UK Sniper In-Line Low Light System (SILLS) - Long Wave InfraRed (LWIR) Weapon Sight 2 requirement.
The deal was awarded after an international tender and is worth up to £8.25 million ($11.43 million) over five years, according to the official MoD contract notice published on 31 August.
Delivery of the initial batch is to be completed by 2022, with options to provide additional units.
Theon is working with its UK-based partner Active Electronics to fulfil the contract.
Shephard Defence Insight notes that the Thermis family of uncooled thermal sights comprises three variants – a light sight intended for use on 5.56mm and 7.62mm assault rifles; a medium sight designed for 5.56mm and 7.62mm machine guns; and a heavy sight for .50cal/12.7mm machine guns and 40mm automatic grenade launchers.
Related Equipment in Defence Insight
More from Land Warfare
-
Canada places $231 million order for 85 Rheinmetall HX trucks
Canada has become the 21st country to have ordered or operate HX trucks, of which more than 10,000 platforms have been sold in 4x4, 6x6 and 8x8 configurations worldwide.
-
Lockheed Martin to increase PAC-3 MSE production by 70%
The company manufactured 380 missiles in 2023 and plans to build 650 missiles per year from 2027.
-
Latvia enters talks to buy GDELS ASCOD IFV
The ASCOD is in service with, or has been ordered by, five countries. In the UK it forms the basis of the British Army’s Ajax and for the US it is the chassis for the M10 Booker.
-
Latvia orders more Patria 6x6 vehicles
The first Latvian-made Common Armoured Vehicle System (CAVS) 6x6 armoured personnel carrier was delivered to the Latvian National Armed Forces (NAF) in August, and more than 200 vehicles are expected to be delivered by 2029.
-
Canadian tech firm makes promise to increase precision and longevity of weapons
Supplied by Paradigm Shift, EPVD technology has undergone trials with the US and Canadian services.